孤立性髂内动脉瘤腔内治疗:十年单中心回顾性研究
该单中心回顾性研究纳入2014至2024年间45例孤立性髂内动脉瘤患者(共49个动脉瘤),评估腔内治疗的安全性与疗效。主要采用支架移植物联合弹簧圈栓塞,技术成功44例,12个月和24个月免再干预生存率分别为95.5%和88.2%,但远端分支完全栓塞率仅69.0%,未完全栓塞者出现瘤囊扩张。
要点
- 腔内治疗孤立性髂内动脉瘤安全有效,中期免再干预生存率85.25%。
- 支架联合弹簧圈栓塞是主要方式,但远端分支完全栓塞率仅69.0%。
- 未完全栓塞远端分支者需严密随访,警惕瘤囊扩张及再干预。
核心结论
- 腔内治疗尤其支架联合弹簧圈栓塞对孤立性髂内动脉瘤安全有效,中期免再干预生存率85.25%,盆腔缺血风险可接受。
- 远端分支完全栓塞在部分病例中技术困难,瘤囊栓塞作为替代方案的疗效尚存争议。
研究设计与样本
- 单中心回顾性研究,纳入2014年4月至2024年4月收治的45例孤立性髂内动脉瘤患者(共49个动脉瘤)。
- 收集患者人口学、干预结果及随访资料进行分析。
主要发现
- 45例患者中仅2例女性,平均年龄70.4±9.2岁,31.1%有恶性肿瘤病史,66.7%为偶然发现。
- 3例单纯支架置入,5例单纯弹簧圈栓塞,37例联合治疗;技术成功44例,远端分支完全栓塞率69.0%(29/42)。
- 平均随访23.8±21.5个月,5例死于癌症或心衰,7例出现臀部跛行(仅1例保守治疗未缓解)。
- 4例未完全栓塞远端分支者出现瘤囊扩张,其中3例需再干预。
- 12个月和24个月免再干预生存率分别为95.5%和88.2%。
关键数值与推荐
- 远端分支完全栓塞率69.0%(29/42)。
- 12个月免再干预生存率95.5%,24个月88.2%。
- 中期免再干预生存率85.25%。
临床怎么用
- 对孤立性髂内动脉瘤可优先考虑支架联合弹簧圈栓塞的腔内治疗。
- 术中应尽量实现远端分支完全栓塞,未完全栓塞者需加强随访监测瘤囊扩张。
- 关注术后盆腔缺血表现如臀部跛行,多数可经保守治疗缓解。
局限性
- 单中心回顾性设计,样本量有限(45例)。
- 随访时间中等(平均23.8个月),远期结果未知。
- 瘤囊栓塞替代方案的疗效尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Isolated internal iliac artery aneurysm (IIIAA) is a rare condition, accounting for approximately 0.3% to 0.5% of all intra-abdominal aneurysms. This study aimed to evaluate the outcomes of endovascular treatment for IIIAA using a relatively large cohort. METHODS: A retrospective analysis was conducted on 45 patients diagnosed with IIIAA who were admitted to our hospital between April 2014 and April 2024. Patient demographics, intervention outcomes, and follow-up results were collected and analyzed. RESULTS: A total of 45 patients (only 2 female) with 49 IIIAAs were included, with a mean age of 70.4±9.2 years. The cohort exhibited a high prevalence of cardiovascular and cerebrovascular risk factors, and 31.1% had a history of malignancy. Thirty patients (66.7%) were diagnosed with an incidental IIIAA, while the remaining patients presented with symptoms such as abdominal or lumbar pain, dysuria, or aneurysm rupture. Stent-graft placement alone was performed in 3 patients, coil embolization alone in 5 patients, and the remaining 37 patients underwent a combined approach. The rate of complete distal branch embolization was 69.0% (29/42), and technical success was achieved in 44 patients. The mean follow-up duration was 23.8±21.5 months. During follow-up, 5 patients died from cancer or heart failure. Buttock claudication was observed in 7 patients, with only 1 case remaining unresolved after conservative treatment. Sac dilation was noted in 4 patients who had incomplete distal branch embolization; of these, 3 required re-intervention. The 12-month and 24-month re-intervention-free survival rates were 95.5% and 88.2%, respectively. CONCLUSION: Endovascular treatment, particularly the combination of stent-graft implantation and coil embolization, is both safe and effective for IIIAA, with a mid-term re-intervention-free survival rate of 85.25% and an acceptable risk of pelvic ischemia. Complete embolization of the outflow branches is technically challenging in some cases, and the efficacy of sac embolization as an alternative remains debatable.Clinical ImpactIsolated internal iliac artery aneurysm (IIIAA) is an exceedingly rare condition. This retrospective study identified and included 45 patients with IIIAA who were treated at our institution to evaluate the safety and therapeutic efficacy of endovascular treatment. The majority of patients underwent stent-graft implantation to seal the internal iliac artery ostium, along with coil embolization of the distal branches. The 2-year reintervention-free survival rate for all patients was 85.25%, demonstrating the favorable efficacy of endovascular treatment. However, postoperative sac dilation was observed in 4 patients who did not receive complete distal branch embolization, emphasizing the need for rigorous follow-up in this subset of patients.
引用
- Liu H, Zou L, Jiang X, et al. Endovascular Treatment for Patients With Isolated Internal Iliac Artery Aneurysm: A Single-Center Retrospective Study Over a 10-Year Period. J Endovasc Ther. 2026. PMID: 41482836. doi:10.1177/15266028251408977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。